Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.63 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.63 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458641 | 0.89 | SIGMAR1 (0.69) | SLC18A3DRD2SIGMAR1CARM1PRMT6 | |
| SCHEMBL2097765 | 0.88 | SIGMAR1 (0.69) | SLC18A3DRD2SIGMAR1CARM1PRMT6 | |
| SCHEMBL9434095 | 0.86 | SIGMAR1 (0.70) | SLC18A3DRD2SIGMAR1CARM1PRMT6 | |
| SCHEMBL4053722 | 0.85 | SLC18A3 (0.62) | SLC18A3DRD2SIGMAR1CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL7259165 | 0.83 | SIGMAR1 (0.75) | SLC18A3DRD2SIGMAR1CARM1PRMT6 | |
| SCHEMBL7660501 | 0.82 | DRD2 (0.58) | SLC18A3DRD2SIGMAR1 | |
| SCHEMBL3399715 | 0.81 | DRD2 (1.00) | SLC18A3DRD2SIGMAR1CARM1PRMT6 | |
| SCHEMBL9369758 | 0.81 | SLC18A3 (0.69) | SLC18A3DRD2SIGMAR1CARM1PRMT6 | |
| SCHEMBL7398128 | 0.81 | SLC18A3 (0.69) | SLC18A3DRD2SIGMAR1CARM1PRMT6 | |
| SCHEMBL11027135 | 0.81 | SLC18A3 (0.69) | SLC18A3DRD2SIGMAR1CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0537008-B1 | Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes | SQUIBB & SONS INC (US) | 1995-10-25 | — | — | EP | claimed |
| US-5276150-A | Vasodilators, anticoagulants, calcium channel blockers | FUJIREBIO INC. (JP) | 1994-01-04 | — | — | US | claimed |
| EP-0537008-A1 | Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes | E.R. SQUIBB & SONS, INC. (US) | 1993-04-14 | — | — | EP | claimed |
| EP-0513760-A2 | Use of biphosphonate squalene synthetase inhibitors in pharmaceutical compositions useful in lowering cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-11-19 | — | — | EP | claimed |
| EP-0400660-A1 | 1,4-dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1990-12-05 | — | — | EP | claimed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101068810-B | Carbostyril compound | OTSUKA PHARMA CO LTD | 2011-02-09 | — | — | CN | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| EP-0537008-B1 | Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes | SQUIBB & SONS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5276150-A | Vasodilators, anticoagulants, calcium channel blockers | FUJIREBIO INC. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0537008-A1 | Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes | E.R. SQUIBB & SONS, INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| EP-0513760-A2 | Use of biphosphonate squalene synthetase inhibitors in pharmaceutical compositions useful in lowering cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| EP-0400660-A1 | 1,4-dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | SLC18A3 4867/4885DRD2 3182/4885SIGMAR1 2794/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | SLC18A3 4612/4885DRD2 947/4885SIGMAR1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.